Inovio starts Ph II of HPV vaccine VGX-3100

Inovio Pharmaceuticals Inc. (NASDAQ:INO) began a Phase II trial to evaluate intramuscular VGX-3100 in 36 patients with vulvar intraepithelial neoplasia (VIN). The open-label trial is evaluating the primary endpoint of clearance of high-grade lesions and virologic clearance of the HPV virus in vulvar tissue, as well as safety.

ApolloBio Corp. (NEEQ:430187) has exclusive rights to develop and commercialize VGX-3100 in Taiwan and China, including Hong Kong and Macau, to treat or prevent pre-cancerous infections and dysplasias tied to HPV (see BioCentury, Feb. 16)...